Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western Thailand
The spread of carbapenem-resistant Enterobacterales (CRE) constitutes a global health burden. Antimicrobial susceptibility and types of carbapenemase differ by geographic region. This study aimed to (1) examine the minimum inhibitory concentrations (MICs) and antibiotic resistance genes and (2) inve...
Saved in:
Main Authors: | Parnrada Nulsopapon (Author), Manat Pongchaidecha (Author), Worapong Nasomsong (Author), Pitimon Polwichai (Author), Sirilada Suphankong (Author), Pantip Sirichote (Author), Siriwan Chaisomboonpan (Author), Wichai Santimaleeworagun (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant <em>Klebsiella pneumoniae</em> Isolates
by: Parnrada Nulsopapon, et al.
Published: (2021) -
Correction: Nulsopapon et al. The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Isolates. <i>Antibiotics</i> 2021, <i>10</i>, 736
by: Parnrada Nulsopapon, et al.
Published: (2022) -
Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>
by: Worapong Nasomsong, et al.
Published: (2022) -
The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Klebsiella pneumoniae Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital
by: Nasomsong W, et al.
Published: (2021) -
Carbapenem-resistant Enterobacterales susceptibility patterns to new antimicrobials: A single-center analysis
by: Miranda Monk, et al.
Published: (2023)